PhRMA: The ‘pill penalty’ imperils cancer drug gains
Earlier this summer, I had a front-row seat for the amazing progress biopharmaceutical companies are making in the battle against cancer. The deluge of data at this year’s American Society for Clinical Oncology (ASCO) meeting provided many reasons to cheer.